Abstract: The disclosure relates to modified orthopoxvirus vectors, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified orthopoxvirus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences and safety. The viruses we have discovered are also amenable to large scale manufacturing protocols.

Abstract: Provided herein is a scar dressing formulation comprising a blend of a high molecular weight silicone elastomer crosspolymer and a silicone oil, wherein said silicone elastomer crosspolymer is in a volatile fluid. The formulation has a soft, silky feel without being greasy and dries quickly to form a durable, flexible scar dressing.

Abstract: Provided herein is a scar dressing formulation comprising a blend of a high molecular weight silicone elastomer crosspolymer and a silicone oil, wherein said silicone elastomer crosspolymer is in a volatile fluid. The formulation has a soft, silky feel without being greasy and dries quickly to form a durable, flexible scar dressing.

Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation in a gel cap. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Abstract: The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals whose inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production, the invention proposes to assist in weight loss by improving the inefficient production of energy by the respiratory transport chain of mitochondria. The invention is useful for the management of the metabolic syndrome, a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well as generally in the body is part of the benefit of the combination of liposomal reduced glutathione and 1-arginine.

Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Abstract: Compositions and methods for delivery of medicaments to human or animal skin, for example, the scalp, comprising the steps of transporting the medicaments in a volatile carrier solution to a position adjacent to the skin, and atomizing the preparation at said position onto the skin to thereby uniformly distribute the preparation over the scalp thereby improving absorption of the medicament through the skin.

Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.

Abstract: The invention relates to methods of promoting wound healing and reducing scar formation by administration of corticosteroids, and pharmaceutical compositions comprising corticosteroids.

Abstract: A cosmetic treatment process is provided herein useful for reducing fine lines, wrinkles, or fine lines and wrinkles. The process comprises contacting a composition to an area of the skin or tissue of a subject, wherein the composition comprises a substance encapsulated within a lipid vesicle comprising a lipid having one or more polyethylene glycol (PEG) chains. The lipid vesicle has a charged surface, and an electric voltage is applied directly to the area of the skin that is contacted with the composition, whereby fine lines, wrinkles, or fine lines and wrinkles are reduced.

Abstract: Compositions and methods for delivery of medicaments to human or animal skin, for example, the scalp, comprising the steps of transporting the medicaments in a volatile carrier solution to a position adjacent to the skin, and atomizing the preparation at said position onto the skin to thereby uniformly distribute the preparation over the scalp thereby improving absorption of the medicament through the skin

Abstract: The present invention provides compositions and methods for treating pain by the administration of analgesics. The analgesics are encapsulated in diacylglycerol-polyethyleneglycol (DAG-PEG) liposomes and delivered sublingually as aerosols.

Abstract: Disclosed herein are sustained release formulations of nifedipine and dextromethorphan that are compatible with a soft elastic gelatin capsule and a two-piece hard shell gelatin capsule. It has been discovered that specific lipids in the formulations can spontaneously form multilamellar liposomes upon introduction of the formulation to an aqueous environment. These spontaneously formed liposomes are stable under conditions that simulate the environment of the stomach and upper small intestine. The formulations can be administered orally, intra-ocularly, intranasally, rectally, or vaginally.

Abstract: A liposome-capsule dosage unit system for the delivery of a biologically active material is formed by encapsulating a biologically active materials in liposomes and then placing the liposome encapsulated material into a capsule. The capsule is typically a soft gel capsule or a two piece capsule capable of tolerating a certain amount of water. A less water tolerant capsule can be employed if the liposomes are dehydrated prior to placement within the capsule. Biologically active material include drugs, nutritional supplements, vitamins, minerals, enzymes, hormones, proteins and polypeptides. The system is especially suited for the delivery of materials with poor oral solubility, materials that are not absorbed or are poorly absorbed from the gastrointestinal tract, and materials that have conventionally been given by an invasive route. The system can be administered orally, intra-occularly, intranasally, rectally, or vaginally.

Abstract: A cosmetic treatment process is provided herein useful for reducing fine lines, wrinkles, or fine lines and wrinkles. The process comprises contacting a composition to an area of the skin or tissue of a subject, wherein the composition comprises a substance encapsulated within a lipid vesicle comprising a lipid having one or more polyethylene glycol (PEG) chains. The lipid vesicle has a charged surface, and an electric voltage is applied directly to the area of the skin that is contacted with the composition, whereby fine lines, wrinkles, or fine lines and wrinkles are reduced.

Abstract: Disclosed herein are sustained release formulations of nifedipine and dextromethorphan that are compatible with a soft elastic gelatin capsule and a two-piece hard shell gelatin capsule. It has been discovered that specific lipids in the formulations can spontaneously form multilamellar liposomes upon introduction of the formulation to an aqueous environment. These spontaneously formed liposomes are stable under conditions that simulate the environment of the stomach and upper small intestine. The formulations can be administered orally, intra-ocularly, intranasally, rectally, or vaginally.

Abstract: The present invention provides compositions and methods of administering nutritional supplements. The compositions and methods of the present invention are based on nutritional supplements that are encapsulated in lipid vesicles for administration as an aerosol or liquid droplet spray.

Abstract: A liposome-capsule dosage unit system for the delivery of a biologically active material is formed by encapsulating a biologically active materials in liposomes and then placing the liposome encapsulated material into a capsule. The capsule is typically a soft gel capsule or a two piece capsule capable of tolerating a certain amount of water. A less water tolerant capsule can be employed if the liposomes are dehydrated prior to placement within the capsule. Biologically active material include drugs, nutritional supplements, vitamins, minerals, enzymes, hormones, proteins and polypeptides. The system is especially suited for the delivery of materials with poor oral solubility, materials that are not absorbed or are poorly absorbed from the gastrointestinal tract, and materials that have conventionally been given by an invasive route. The system can be administered orally, intra-occularly, intranasally, rectally, or vaginally.